男性性腺機能低下症:治療薬開発パイプライン分析

◆英語タイトル:Male Hypogonadism - Pipeline Review, H1 2018
◆商品コード:GMDHC10105IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年1月23日
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥648,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における男性性腺機能低下症の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・男性性腺機能低下症の概要
・男性性腺機能低下症治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・男性性腺機能低下症パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・男性性腺機能低下症治療薬開発に取り組んでいる企業:企業別製品パイプライン
・男性性腺機能低下症治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Male Hypogonadism – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism – Pipeline Review, H1 2018, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 4, 5, 2 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism – Overview
Male Hypogonadism – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism – Companies Involved in Therapeutics Development
Antares Pharma Inc
Clarus Therapeutics Inc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
Repros Therapeutics Inc
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism – Drug Profiles
BGS-649 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone enanthate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism – Dormant Projects
Male Hypogonadism – Discontinued Products
Male Hypogonadism – Product Development Milestones
Featured News & Press Releases
Jan 10, 2018: Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism
Dec 15, 2017: Repros Therapeutics Receives Feedback Following an Oral Explanation with the European Medicines Agency
Dec 06, 2017: Acerus Enters into Loan Facility to Support Anticipated Product Launch and Sales and Marketing Initiatives
Nov 30, 2017: Acerus Secures CDN$1.6M of New NATESTO Orders from Its U.S. Licensee Aytu Bioscience
Nov 28, 2017: Aytu BioScience Provides Update on the Continued Growth of Natesto in the U.S.
Nov 17, 2017: U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged
Oct 26, 2017: Aytu BioScience Provides Quarterly Update on the Natesto U.S. Launch
Oct 18, 2017: FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018
Sep 26, 2017: Aytu BioScience Provides Update on the Natesto U.S. Launch
Sep 20, 2017: Lipocine Announces FDA Advisory Committee Meeting for TLANDO
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
Aug 14, 2017: Lipocine Announces FDA Acknowledgement of TLANDO (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018
Aug 09, 2017: Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism
Jun 26, 2017: Clarus Re-submits JATENZO NDA Following Positive Results of inTUne Trial
Jun 19, 2017: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Male Hypogonadism, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Male Hypogonadism - Pipeline by Antares Pharma Inc, H1 2018
Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H1 2018
Male Hypogonadism - Pipeline by EndoCeutics Inc, H1 2018
Male Hypogonadism - Pipeline by Ferring International Center SA, H1 2018
Male Hypogonadism - Pipeline by Lipocine Inc, H1 2018
Male Hypogonadism - Pipeline by M et P Pharma AG, H1 2018
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H1 2018
Male Hypogonadism - Pipeline by Merck & Co Inc, H1 2018
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H1 2018
Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H1 2018
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H1 2018
Male Hypogonadism - Pipeline by Viramal Ltd, H1 2018
Male Hypogonadism - Dormant Projects, H1 2018
Male Hypogonadism - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Male Hypogonadism, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

【レポートのキーワード】

男性性腺機能低下症

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[男性性腺機能低下症:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆